Intrathecal Infusion of Autologous Adipose-Derived Regenerative Cells in Autoimmune Refractory Epilepsy: Evaluation of Safety and Efficacy

Table 1

Inclusion and exclusion criteria for the intrathecal ADRC treatment.

Inclusion criteria	Exclusion criteria
(i) Presence of antineuronal antibody in serum or CSF	(i) Refractory epilepsy with proven genetic or metabolic etiology
(ii) Rasmussen encephalitis (proven cellular immunity pathogenesis)	(ii) Neoplastic process
(iii) Probable autoimmune pathogenesis (autoimmune diseases in family, FIRES—febrile infection-related epilepsy syndrome)	(iii) Status epilepticus
(iv) Patient’s or parents’ agreement	(iv) Infection